ArticleBriefings in bioinformatics2025
AttBiomarker: unveiling preeclampsia biomarkers and molecular pathways through two-stage gene selection techniques and attention-based CNN with gene regulatory network analysis.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A hybrid machine learning framework with two-step feature selection for identifying key biomarkers and drug targets in monkeypox.Biochemistry and biophysics reports · 2026Article
- Mechanism-Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precision Biomarker Identification in Gynecological Cancers Using Coexpression Networks and Attention-Based LSTM in Healthcare 4.0.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Preeclampsia is a complex pregnancy disorder that poses significant health risks to both mother and fetus. Despite its clinical importance, the underlying molecular mechanisms remain poorly understood. In this study, we developed an integrative deep learning and bioinformatics approach to identify potential biomarkers for preeclampsia. Three microarray datasets related to preeclampsia were initially analyzed to select a preliminary gene subset based on $P$-values. Feature selection was then performed in two consecutive rounds: first, the Fisher score method was applied to extract significant genes, followed by the minimum Redundancy Maximum Relevance method to refine the subset further. These selected gene subsets were trained using our proposed Attention-based Convolutional Neural Network (AttCNN), which achieved the highest classification accuracy compared with other models. From the experiments, a set of 58 common genes was identified between differentially expressed genes and the final optimized subset. Here, Gene Ontology and KEGG pathway enrichment analyses highlighted key biological processes and pathways associated with preeclampsia. Subsequently, a protein-protein interaction network was constructed, identifying 10 hub genes: TSC22D1, IRF3, MME, SRSF10, SOD1, HK2, ERO1L, SH3BP5, UBC, and ZFAND5. Further analysis of gene regulatory networks, including transcription factor-gene, gene-microRNA, and drug-gene interactions, revealed that seven hub genes (HK2, SRSF10, SOD1, ERO1L, IRF3, MME, and SH3BP5) were strongly associated with preeclampsia. Molecular docking analysis showed that HK2, SH3BP5, and SOD1 exhibited significant binding affinities with two preeclampsia drugs. These findings suggest that the identified hub genes hold promise as biomarkers for early prognosis, diagnosis, and potential therapeutic targets for preeclampsia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.